Rebecca Roberts in The Scientist:
In her five years as a clinician treating blood cancers, Elizabeth Goodall noticed a critical failure point: Many patients who wanted to enroll in clinical trials or try a new drug were being told they couldn’t. “I listened to patients not only describe their symptoms, but also heard their confusion and disappointment if they were not eligible for a clinical trial or new therapy that they were desperate to have access to, for often quite arbitrary reasons,” said Goodall, who is now a PhD candidate at the Oliver Newton-John Cancer Research Institute.
To further dig into this issue, Goodall and her colleagues systematically evaluated ongoing clinical trials for diffuse large B-cell lymphoma (DLBCL) and applied the trials’ eligibility criteria to real-world patients. This research showed that based on eligibility criteria, not a single person in a real-world cohort of 180 relapsed DLBCL patients would qualify for all seven recent DLBCL clinical trials that led to landmark drug approvals.
More here.
Enjoying the content on 3QD? Help keep us going by donating now.